Search clinical trials for: GDC 268 Lotion

Total 97956 results

Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
Alkermes, Inc.

Recruiting

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) (Vibrance-1)

Narcolepsy Type 1

United States
AnHeart Therapeutics Inc.

Recruiting

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Cholangiocarcinoma With IDH1 Mutation | Solid Tumors With IDH1 Mutation

China
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
Gesynta Pharma AB
Ergomed

Completed

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Systemic Sclerosis

United Kingdom, Poland, Belgium, Netherlands
Carmot Therapeutics, Inc.

Active, not recruiting

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Obesity | Type2 Diabetes

United States, Mexico
Dana-Farber Cancer Institute
Kazia Therapeutics Limited

Recruiting

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Breast Cancer

United States
University of Thessaly

Completed

SuPAR in Adult Patients With Covid-19 (SPARCOL)

Covid19

Greece
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
AbbVie
Roche-Genentech

Completed

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Renal Impairment | Renal Disease

United States
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

Nasopharyngeal Cancer

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Not yet recruiting

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Hoffmann-La Roche

Completed

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

United States
M.D. Anderson Cancer Center
Amgen

Withdrawn

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Type 1 Diabetes

United States, Italy, Canada, United Kingdom, Switzerland, Netherlands, Germany
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Zeria Pharmaceutical

Completed

Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

Japan
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.

Pain

United States
AlgoRx Pharmaceuticals

Completed

Study of ALGRX 3268 for Needlestick Pain in Children

Pain

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
Genentech, Inc.

Completed

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumor

United States, Korea, Republic of, Spain, France
University of Thessaly

Completed

Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) (SPARSE)

Surgery--Complications

Greece
Atrogi AB

Recruiting

The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers (Attractive 2)

Type2diabetes

Sweden
Genentech, Inc.

Completed

A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin

Healthy Participants

United States
Genentech, Inc.

Terminated

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Breast Cancer

United States, Korea, Republic of, Spain, Netherlands
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-208

Androgenetic Alopecia

Korea, Republic of
M.D. Anderson Cancer Center
AbbVie; Syndax Pharmaceuticals; Break Through Cancer

Not yet recruiting

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Acute Myeloid Leukemia

United States
AbbVie
Astellas Pharma Inc; Genentech, Inc.

Completed

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States
Stryker Neurovascular

Completed

MAPS Trial: Matrix And Platinum Science (MAPS)

Intracranial Aneurysms

United States, Germany, Canada, Spain, Norway, Australia, China, France, Mexico, Turkey, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Metastatic Skin Squamous Cell Carcinoma | Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Refractory Malignant Neoplasm | Appendix Adenocarcinoma | Locally Advanced Malignant Neoplasm | Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Metastatic Small... and other conditions

United States
Fox Chase Cancer Center
Knowledge Networks

Completed

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men

Prostate Cancer

United States
Sunnybrook Health Sciences Centre

Active, not recruiting

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Melanoma

Canada
Genentech, Inc.

Completed

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

China
Addpharma Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of AD-218

Mixed Dyslipidemia

Korea, Republic of
Resverlogix Corp

Withdrawn

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

Fabry Disease

Canada
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

A Food Effect Study of LP-168 Tablets in Healthy Subjects

Mantle Cell Lymphoma

China
Resverlogix Corp

Completed

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease (ASSERT)

Coronary Artery Disease | Atherosclerosis

United States
Molecular NeuroImaging

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

B-cell Lymphoma

China
Bradley A. McGregor, MD
Calithera Biosciences, Inc

Completed

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-668

Alpha-1 Antitrypsin Deficiency

United States
Eli Lilly and Company
Loxo Oncology, Inc.

No longer available

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms
Atrogi AB
Key2Compliance; CRS Clinical Research Services

Completed

First-in-human Single and Multiple Dose Trial of ATR-258

Type 2 Diabetes Mellitus

Germany
IGM Biosciences, Inc.

Terminated

Evaluation of IGM-6268 in Healthy Volunteers

Healthy Volunteers

United States
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

China
M.D. Anderson Cancer Center
Novartis

Completed

TKI258 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States

Search clinical trials for: GDC 268 Lotion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations